Alex joined BioTechLogic in 2013 as a Senior Consultant in analytical sciences and returned in 2023 as Director of BD. He joined DHC's Business Development team at the time of BioTechLogic's acquisition.
Alex joined BioTechLogic in 2013 as a Senior Consultant in analytical sciences. He had previously held technical positions at Novartis and Amgen. He left BioTechLogic to pursue an analytical position at CSL Seqirus before eventually transitioning his career toward business development at KBI Biopharma and Resilience.
In 2023, Alex returned to BioTechLogic as the Director of Business Development. He applies his analytical science experience and business development expertise to help biopharmaceutical developers, including gene and cell therapy organizations, advance their therapeutics to market faster.
With over two decades of experience in the biotechnology industry, specializing in business development and technical strategy, Alex is known for his ability to recognize and capitalize on growth opportunities. Alex has a track record of driving business expansion, building productive partnerships, and leading high-performing teams. His career reflects a blend of technical expertise and empathetic leadership, enabling him to navigate complex business landscapes and foster solid and lasting relationships.
In his recent role as Director of Business Development with Resilience, Alex was responsible for global sales efforts in the vaccine sector. He successfully expanded relationships with legacy partners and attracted new business opportunities. His collaborative approach allowed him to work effectively with cross-functional teams, including technical leaders, marketing, and legal, to devise impactful content and strategies that elevated client engagement.
Before joining Resilience, Alex served in key roles at KBI Biopharma, managing a global business development portfolio focused on analytics. As an Associate Director and later Director of Business Development, he played a pivotal role in technical sales and proposal generation, securing high-value contracts and overseeing complex project portfolios. His analytical science leadership during the COVID-19 pandemic was marked by growth and adaptability, expanding his team and maintaining morale and productivity in challenging circumstances.
Alex began his career as a scientist with positions at major firms such as Novartis and Amgen, where he developed his technical expertise. His academic foundation includes a Bachelor of Science in Biology with Ecology from the University of East Anglia, and he has continued to refine his skills through advanced negotiation training. This combination of scientific knowledge, strategic insight, and relationship-building acumen has made Alex a respected figure in the biotechnology community and a trusted partner for clients navigating the intricacies of regulatory compliance and commercialization.
